Harmony Biosciences

US · HRMY #2681 by market cap Listed 2020

39.34 -0.02 -0.05%

Live - 5344 symbols - heartbeat 249s ago · 2026-10-08 08:33

Pre-market 39.32 -0.05%

After-hours 39.25 -0.23%

Overnight 38.91 -1.09%

Market cap: 2.29B
P/E (TTM): 12.73
P/B: 2.29
EPS: 2.71
Div yield: 0.00%
52W pos: 77%

Reader sentiment Are you bullish or bearish on HRMY?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Ownership Signal how this is computed

Distributing

Total institutional ownership fell 0.3 percentage points.

Institutional ownership

Held by institutions: 107.90% -0.30pp
Institutions: 394
As of: 2026/Q3 vs. prior period

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Holder types

Mutual Fund68.43%

Hedge Fund13.74%

Private Company13.59%

VC/PE Fund5.95%

Public Company3.69%

Government Pension Fund1.28%

Family Office/Trust0.74%

Sovereign Wealth Fund0.25%

Bank/Investment Bank0.12%

Top holders as of 2026-06-30

BlackRock 12.20% · 7.10M sh

Marshman Fund Trust II 10.39% · 6.05M sh

FMR 6.14% · 3.57M sh

Vanguard Portfolio Management, LLC 4.95% · 2.88M sh

American Century Investment Management 4.36% · 2.54M sh

Vanguard Capital Management, LLC 4.13% · 2.40M sh

Dimensional Fund Advisors 4.11% · 2.39M sh

HBM Healthcare Investments AG 3.69% · 2.15M sh

LSV Asset Management 3.54% · 2.06M sh

State Street Global Advisors 3.19% · 1.86M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 24 buys · 23 sells

Name	Role	Stake
Marshman Fund Trust II	--	10.39%
Sandip Kapadia	Executive VP, Chief Administrative Officer & CFO	0.04%
Kumar Budur	Chief Medical Officer	0.02%
Jeffrey Dayno	Chief Executive Officer	0.02%
Andrew Serafin	Chief Strategy Officer	0.01%
Adam Zaeske	EVP & Chief Commercial Officer	0.01%
Stephen Mollichella	Senior VP, Controller & Interim Principal Financial Officer	0.00%
Jeffrey Aronin	Non-Executive Chairperson	0.00%
R. Graf	Independent Director	--
Gary Sender	Independent Director	--

Insider transactions most recent Form 4 filings

Date	Name	Role	Type	Shares	Price
2026-09-17	Kumar Budur	Chief Medical Officer	Derivative Exercise and Sale	-38,452	$30.27–43.05
2026-09-17	Kumar Budur	Chief Medical Officer	Intent to Sell (Form 144)	-35,852	$42.74
2026-09-16	Kumar Budur	Chief Medical Officer	Intent to Sell (Form 144)	-800	$42.21
2026-09-15	Kumar Budur	Chief Medical Officer	Intent to Sell (Form 144)	-1,800	$42.17
2026-09-07	Kumar Budur	Chief Medical Officer	Automatic Disposition	-11,000	$41.98–42.79
2026-09-07	Kumar Budur	Chief Medical Officer	Derivative Exercise and Sale	-22,954	$30.27–43.10
2026-09-03	Kumar Budur	Chief Medical Officer	Intent to Sell (Form 144)	-5,500	$41.86
2026-08-06	Valor Management LLC	--	Intent to Sell (Form 144)	-700,883	$37.90
2026-07-15	Stephen Mollichella	Senior VP, Controller & Interim Principal Financial Officer	Initial Statement of Beneficial	0	--
2026-07-01	Sandip Kapadia	Executive VP, Chief Administrative Officer & CFO	Intent to Sell (Form 144)	-25,000	$36.96
2026-06-29	Sandip Kapadia	Executive VP, Chief Administrative Officer & CFO	Intent to Sell (Form 144)	-50,000	$36.08
2026-06-25	Sandip Kapadia	Executive VP, Chief Administrative Officer & CFO	Intent to Sell (Form 144)	-45,594	$35.24
2026-06-23	Sandip Kapadia	Executive VP, Chief Administrative Officer & CFO	Intent to Sell (Form 144)	-4,406	$35.02
2026-06-08	Sandip Kapadia	Executive VP, Chief Administrative Officer & CFO	Intent to Sell (Form 144)	-27,960	$33.74
2026-06-04	Sandip Kapadia	Executive VP, Chief Administrative Officer & CFO	Intent to Sell (Form 144)	-2,101	$33.08
2026-06-03	Sandip Kapadia	Executive VP, Chief Administrative Officer & CFO	Intent to Sell (Form 144)	-7,064	$33.02
2026-05-13	R. Graf	Independent Director	Other Derivative Acquisition	+21,872	$30.76
2026-05-13	Gary Sender	Independent Director	Other Derivative Acquisition	+21,872	$30.76
2026-05-13	Linda Szyper	Independent Director	Other Derivative Acquisition	+21,872	$30.76
2026-05-13	Geno Germano	Independent Director	Other Derivative Acquisition	+21,231	$30.76

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-10-08 08:33:53 · For reference only, not investment advice and not tailored to your situation.